

CDK12-IN-6 biochemical

CDK12-IN-6

CATALOG #
AAA228568


PRODUCT SYNONYMS

CDK12-IN-6; AZP-2006; CDK12-IN-6 biochemical


PRODUCT SPECIFICATIONS

Purity/Purification	98%
CAS	2651196-71-1
Targets&IC50	CDK12:1.19 uM (IC50), CDK2/CyclinE:20 uM (IC50), CDK9/CyclinT1:20 uM (IC50)
Solubility	<1mg/ml refers to the product slightly soluble or insoluble
In vitro	CDK12-IN-6 (Example 174) inhibits BRCA1 mRNA expression in MDA-MB-231 cells (IC 50 =0.872 nM) and has no effect on CAL-120 cells[1]. CDK12-IN-6 has antproliferative activity in MDA-MB-231 cells (IC 50 =2.19 nM) and CAL-120 cells (IC 50 =1 nM)[1]. CDK12-IN-6 has a inhibition IC 50 CDK12 high ATP to Degradation DC 50 CDK12 ratio of 1851[1].
Preparation and Storage	Powder: -20 degree C for 3 years In solvent: -80 degree C for 2 years

IMAGES



Structure
Ezeprogind, CAS 615539-20-3



Structure
Ezeprogind, CAS 615539-20-3

ADDITIONAL INFORMATION

Related Product Information for CDK12-IN-6 biochemical	CDK12-IN-6, a pyrazolotriazine, is a potent CDK12 inhibitor with an IC 50 of 1.19 uM at high ATP (2 mM). CDK12-IN-6 has no effect on CDK2/Cyclin E (IC 50 20 uM) and CDK9/Cyclin T1 (IC 50 20 uM) at high ATP (2 mM)(WO2021116178A1).
References	1. Alzprotect Strengthens Its Intellectual Property Portfolio for Its First-in-Class Clinical Stage Drug Ezeprogind 2. A Study to Assess Tolerability, Safety, Pharmacokinetics and Effect of AZP2006 in Patients With PSP

For Research Use Only. Not for use in diagnostic or therapeutic procedures. Small volumes of product may become entrapped in the seal of the vial during shipment and storage; if necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the cap.

AAA Biotech | Tel: +1 (619) 604-9440 | Fax: +1 (619) 604-9441 | contact@aaabiotech.com
Online datasheet: <https://stage.aaabiotech.com/biochemical/cdk12-in-6/228568>